Figure 1.
Generation of an early-induction DM1 mouse model.
A. Whole mount in-situ hybridization of embryos at different time points showing onset of Dmpk expression (represented by the blue color) is visible only by the 10th day of development (E10). B. Schematic diagram representing the protocol used to generate and study the EDM1 mice and adult-onset mice. The green line represents administration of doxycycline. The red arrow represents induction of the transgene resulting in an increase in toxic RNA. Arrowheads with a P represent phenotypic analysis while the final arrowhead P&T represents phenotypic analysis and tissues collection. C. Induction of the transgene was measured in whole embryos by qRT-PCR at varying time points as indicated. Significant doxycycline mediated transgene induction starts at embryonic day 10, similar to results for endogenous Dmpk (see Figure 1A.). D. Graph of toxic RNA levels in skeletal muscle shows no significant difference between the EDM1 and adult-onset DM1 mice. Number of samples (n) provided on the graph, averages listed in the tables below the graphs, error bars are SEM. Two Sample T-Test was used to determine statistical significance.
Figure 2.
Characterization of EDM1 mice.
A. Myotonia was measured and scored on a 3 point scale with 0 being no myotonia and 3 being strong, persistent, and prevalent myotonia. EDM1 mice show myotonia as early as 2 weeks of age and reached maximal severity by 4 weeks. B. EDM1 mice have a reduction in grip strength as early as 4 weeks of age while the adult-onset mice did not show a significant reduction. C. PR interval was measured in the EDM1 mice. No statistical difference was measured at 2 weeks of age; however the subsequent time points showed a significant lengthening of the interval. Similar but less severe results were observed in the adult-onset DM1 model. Number of samples (n) provided on the graph, averages listed in the tables below the graphs, error bars are SEM. Two Sample T-Test was used to determine statistical significance with p-values of 0.05 (*), 0.01 (**) or <0.001 (***) displayed.
Figure 3.
Histopathology, RNA splicing and CUGBP1 are all altered in the EDM1 mice.
A. H&E staining shows uniform fibers and peripheral nuclei in the wildtype sections. With RNA toxicity, there is an increase in central nuclei (white arrowhead), increase in fiber size variability, and of atrophic fibers (black arrow). B. CUGBP1 is increased in the skeletal muscles of EDM1 mice. C. Clcn1, Nfix, Nrap, Mbnl1, and SmyD1 splicing alterations found in human DM1 are present in the EDM1 mice. Number of samples (n) provided in the tables, averages listed in the tables along with standard deviation. Two Sample T-Test was used to determine statistical significance with p-values displayed.
Figure 4.
Age of onset of toxic RNA expression affects DM1 disease phenotypes.
RNA toxicity animals were compared to control groups for both A) PR interval and B) grip strength. Effects on grip strength and PR interval were more severe in the early induction mice (EDM1) compared to the adult onset mice (Adult-onset DM1). Averages are listed in the tables below the graphs. Error bars are SEM. Groups that do not share a letter are significantly different (p<0.05) using a One-Way ANOVA with Tukey’s Multiple Comparisons. N = 10 or more for each control group used to generate the control average and N = 17 or more for each DM1 group.
Table 1.
Lack of parent of origin effect in the EDM1 mice.
Figure 5.
Partial Rescue of EDM1 phenotype in skeletal muscle by over-expression of MBNL1.
A. RNA-IP using a monoclonal antibody against MBNL1 pulls down the GFP-DMPK 3′UTR mRNA in both the EDM1 and adult-onset DM1 mice but not mice expressing EGFP only. Beads, IgG and RT -ve controls were used to show MBNL1 specificity. EGFP was amplified to detect the transgene. B. MBNL1 was confirmed to be up-regulated by qRT-PCR and C. by western blot analysis in the MBNL1 treated leg but not the EGFP treated leg. D. Median myotonia score in EDM1 mice expressing MBNL1 and EGFP in their TA muscles shows a slight reduction in myotonia due the presence of MBNL1 but not EGFP. E. mRNA splicing was also partially improved for SmyD1. Clcn1-exon7a showed no change. Number of samples (n) provided along with average or median in the tables along with standard deviation. Two Sample T-Test was used to determine statistical significance with p-values displayed.